Huge cuts in aid ahead for HIV/AIDS treatment
‘US government funding is going to come down dramatically over the next five years,’ warned Dr Roxana Rogers, USAID South Africa Health Team leader last week.
‘There is not a friendly feeling in the US towards more funding for HIV/AIDS,’ Rogers told a meeting in Cape Town on the future of US assistance for HIV/AIDS, hosted by the US-based Council on Foreign Relations.
Almost a million South Africans will soon be on lifelong antiretroviral treatment and this number will triple in the next decade if government keeps to its implementation plan.
Yet the prospect of government being able to meet its promise of treating 80 percent of those who need it by 2011 is being threatened by a lack of funds.
In the current budget year, the US President’s Emergency Plan for AIDS Relief (Pepfar) contribution was over R4,3-billion, while government’s total contribution was R5-billion, according Treasury official Dr Mark Blecher.
Two months ago, the US government announced that it would be giving South Africa an extra $120 million (approximately R900 million) ‘in direct response to a request from President Jacob Zuma’ to ‘procure ARVs will help ensure that there are adequate stocks on hand to meet the growing demand for ARVs in South Africa’.
However, Rogers indicated that this contribution had been ‘exceptional’ and was not likely to be repeated.
Scenario planning by Treasury indicates that the demand for treatment and care will peak in 2021, when the country would need close to R30-billion. At present, 40 percent of the HIV/AIDS budget goes to antiretroviral treatment.
‘We are facing a double whammy of having to rapidly scale-up spending on HIV/AIDS at the same time that we have to replace donor funds,’ said Dr Keith Cloete of the Western Cape Treasury.
‘For the next five to 10 years, we need additional funds. This is not the time to pull out funds as programmes are going to collapse,’ said Cloete.
Rogers said that the looming budget cuts were ‘keeping us up at night’ as Pepfar funded the salaries of many of the healthworkers who were implementing government’s HIV/AIDS plan.
She said that USAID officials in South Africa, and the US Global AIDS Ambassador, understood that this country was the ‘epicentre of the epidemic’ and wanted funding for to continue but said South Africa should provide the US with more reports about its successes in addressing the epidemic.
Prof Helen Rees, Reproductive Health and HIV Research Unit director, warned that if Pepfar funding stopped, the fight against HIV/AIDS would ‘go backwards’ and called for a ‘dialogue with the US government’ rather than simply accepting that the funds were to be cut.
However, Dr Thurma Goldman, director of the US Centers for Disease Control in southern Africa, said the plan was not to ‘rapidly reduce’ funds.
‘We are talking about a transition from emergency funding to a transition to mentoring a sustainable programme,’ said Goldman.
‘There will be decreased funding for South Africa but this does not have to mean scaling down. By belt-tightening and rationalising services, we can turn this into a sustainable programme.’
Blecher conceded ‘weak coordination between between provincial and donor funded services’ and ‘fragmentation between large numbers of organisations’ undermined the implementation of a common plan.
He recommended the development of a five-year plan and clear partnership based on an agreed division of ‘responsibilities, services and funding’.
Meanwhile, Professor Alan Whiteside from Health Economics and HIV/AIDS Research Division at the University of KwaZulu-Natal, said that donor funding typically had a three- to five-year time scale, and South Africa needed to move to more sustainable health development funding.
‘We need to get more for our money and be more imaginative. We are an AIDS-afflicted country so we should develop an AIDS economy. We could be training two million people to assist those living with HIV,’ said Whiteside.
Author
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Huge cuts in aid ahead for HIV/AIDS treatment
by Health-e News, Health-e News
January 27, 2010